Inhibikase Therapeutics
IKT
47 hedge funds and large institutions have $113M invested in Inhibikase Therapeutics in 2025 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 12 increasing their positions, 3 reducing their positions, and 3 closing their positions.
533% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 3
300% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 3
52% more funds holding
Funds holding: 31 → 47 (+16)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5.28% less ownership
Funds ownership: 74.5% → 69.23% (-5.3%)
31% less capital invested
Capital invested by funds: $163M → $113M (-$50M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.94M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.27M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$390K |
| 4 |
Goldman Sachs
New York
|
+$307K |
| 5 |
Jane Street
New York
|
+$292K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$1.46M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$546K |
| 3 |
Citigroup
New York
|
-$129K |
| 4 |
Squarepoint
New York
|
-$92.3K |
| 5 |
AGM
Alpine Global Management
New York
|
-$48.2K |
IKT Hedge Fund Activity: Q1 2025 in Review
47 of the 7,476 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q1 2025, worth a combined $113M — down 31% from $163M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new IKT positions and 3 closed out — a net gain of 16 holders — while 12 added to existing stakes and 3 trimmed.
The largest buyer was Millennium Management, adding an estimated $1.94M. The largest seller was Commodore Capital, cutting an estimated $1.46M.
- 47 institutional investors held Inhibikase Therapeutics (IKT) as of Q1 2025, up from 31 in Q4 2024.
- Funds reported $113M of Inhibikase Therapeutics stock for Q1 2025, down 31% quarter-over-quarter.
- 19 funds opened new Inhibikase Therapeutics positions in Q1 2025 and 3 closed out, a net change of +16 holders.
- The largest Inhibikase Therapeutics buyer in Q1 2025 was Millennium Management, an estimated $1.94M added.
- The largest Inhibikase Therapeutics seller in Q1 2025 was Commodore Capital, an estimated $1.46M sold.
Based on aggregated 13F filings for Q1 2025.